Tidligfase utvikling av målrettet radionuklidterapi for solide kreftkreftformer

Offentlig prosjektsammendrag

This project aims to develop a novel targeted radionuclide therapy (TRT) for a rare cancer indication with limited treatment options. The therapeutic concept builds on previous experience with molecular targeting and introduces an alpha-emitting radionuclide to enhance precision and potency. The main challenge is to design targeting molecules that retain their binding properties after conjugation with chelators suitable for alpha therapy—a known hurdle in the field. Through a systematic R&D approach involving chemistry, radiochemistry, and in vitro testing, the project will evaluate several candidate molecules and chelators. If successful, the project could lead to a first-in-class therapeutic option for patients with few alternatives.